AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7707111 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg orally, twice daily for 3 months
Number of subjects: 28
Study 7707111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2496357 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin-dipyridamole (990 mg/225 mg daily)
Number of subjects: 16
Study 580589 — intervention group
Group type: EXPERIMENTAL
Intervention: meproscillarin (4 X 0.25 mg/d for 7 days)
Number of subjects: 11
Study 580589 — intervention group
Group type: COMPARATOR
Intervention: placebo (7 days)
Number of subjects: 11
Study 31253207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion at 1.5 times C0
Number of subjects: 180
Study 31253207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion at 2 times C0
Number of subjects: 180
Study 31253207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion at 2.5 times C0
Number of subjects: 180
Study 29282073 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training, exercises, and pain education combined
Number of subjects: 164
Study 29282073 — intervention group
Group type: COMPARATOR
Intervention: Pain education only
Number of subjects: 164
Study 26721039 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted sutures
Number of subjects: 138
Study 26721039 — intervention group
Group type: COMPARATOR
Intervention: Continuous sutures
Number of subjects: 138
Study 23374763 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water
Number of subjects: 30
Study 23374763 — intervention group
Group type: COMPARATOR
Intervention: Placebo water
Number of subjects: 30
Study 21515482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and docetaxel (DC) regimen with concurrent radiotherapy
Number of subjects: 48
Study 21515482 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (PF) regimen with concurrent radiotherapy
Number of subjects: 48
Study 21515482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and docetaxel (DC) regimen
Number of subjects: 48
Study 21515482 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (PF) regimen
Number of subjects: 48
Study 19456294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric low-fat diet
Number of subjects: 35
Study 19456294 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance diet
Number of subjects: 35
Study 16371610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil 0.05 microg x kg(‐1) /puff
Number of subjects: 40
Study 16371610 — intervention group
Group type: COMPARATOR
Intervention: Intranasal sufentanil 0.025 microg x kg(‐1) /puff
Number of subjects: 40
Study 14986206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorneal ring implantation
Number of subjects: 20
Study 14986206 — intervention group
Group type: COMPARATOR
Intervention: Control group (PKP without intracorneal ring)
Number of subjects: 20
Study 14986206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 11091188 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIL-10 (8 microg/kg/d subcutaneously for 10 days)
Number of subjects: 12
Study 11091188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9307357 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional confidentiality assurance
Number of subjects: 562
Study 9307357 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional confidentiality assurance
Number of subjects: 562
Study 9307357 — intervention group
Group type: COMPARATOR
Intervention: No confidentiality assurance
Number of subjects: 562
Study 8317719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl infusion (0.5 mL saline bolus followed by 120 micrograms fentanyl infusion in 24 h)
Number of subjects: 60
Study 8317719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine infusion (0.5 mL saline bolus followed by 200 micrograms morphine infusion in 24 h)
Number of subjects: 60
Study 8317719 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine bolus (200 micrograms morphine as a single bolus followed by 3 mL saline infusion in 24 h)
Number of subjects: 60
Study 2895171 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers/diuretics
Number of subjects: 4668
Study 2895171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4668
Study 31570566 — intervention group
Group type: EXPERIMENTAL
Intervention: Telapristone acetate (TPA) 12 mg daily for 2 to 10 weeks
Number of subjects: 70
Study 31570566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31570566 — intervention group
Group type: EXPERIMENTAL
Intervention: Telapristone acetate (TPA) in premenopausal women
Number of subjects: 70
Study 31570566 — intervention group
Group type: EXPERIMENTAL
Intervention: Telapristone acetate (TPA) in subset of tumors with ≥30% Ki67 reduction
Number of subjects: 70
Study 28084851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ai Chi exercise group
Number of subjects: 40
Study 28084851 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise control group
Number of subjects: 40
Study 26858426 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (participants who remained awake all night)
Number of subjects: 0
Study 26858426 — intervention group
Group type: COMPARATOR
Intervention: Rested participants (participants who slept all night in laboratory bedrooms)
Number of subjects: 0
Study 25456710 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training alone
Number of subjects: 45
Study 25456710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation alone
Number of subjects: 45
Study 25456710 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (exercise training + ventilation)
Number of subjects: 45
Study 25456710 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 21890575 — intervention group
Group type: EXPERIMENTAL
Intervention: STN‐DBS implants
Number of subjects: 15
Study 20167117 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 500 mg IV
Number of subjects: 220
Study 20167117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 18056144 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release methylphenidate (Ritalin), administered three times a day
Number of subjects: 21
Study 18056144 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 21
Study 16616020 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment within 96 hours of AMI onset
Number of subjects: 486
Study 16616020 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment
Number of subjects: 486
Study 16616020 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 486
Study 12834362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal‐transport‐system (GITS)
Number of subjects: 0
Study 12834362 — intervention group
Group type: COMPARATOR
Intervention: Co‐amilozide (hydrochlorothiazide and amiloride)
Number of subjects: 0
Study 12834362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 0
Study 11206101 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine IV infusion started before PTCA and continued for 48 hours
Number of subjects: 94
Study 11206101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 8828680 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AEX)
Number of subjects: 47
Study 8828680 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL)
Number of subjects: 47
Study 8828680 — intervention group
Group type: EXPERIMENTAL
Intervention: AEX + WL
Number of subjects: 47
Study 8828680 — intervention group
Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 47
Study 1424426 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.1 to 2.3 mg per subject)
Number of subjects: 8
Study 1424426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2867772 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium
Number of subjects: 80
Study 2867772 — intervention group
Group type: COMPARATOR
Intervention: Tubocurarine
Number of subjects: 80
Study 2867772 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 80
Study 2867772 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 80
Study 31631029 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Dix Hallpike/head-roll test for benign paroxysmal positional vertigo
Number of subjects: 305
Study 31631029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular medication use
Number of subjects: 305
Study 31631029 — intervention group
Group type: EXPERIMENTAL
Intervention: High postural sway when standing on the floor with eyes closed (sway path ≥160 mm)
Number of subjects: 305
Study 31631029 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety (Generalized Anxiety Disorder Scale 7-item Scale score ≥8)
Number of subjects: 305
Study 31631029 — intervention group
Group type: COMPARATOR
Intervention: Age 70 years and over
Number of subjects: 305
Study 29917190 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhepatic arterial chemoembolization (TACE)
Number of subjects: 110
Study 26833462 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0114‐0005 (0.0025‐25 mg/kg)
Number of subjects: 64
Study 26833462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 26833462 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0114‐0005 (25 mg/kg)
Number of subjects: 64
Study 26833462 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0114‐0005
Number of subjects: 64
Study 24762049 — intervention group
Group type: EXPERIMENTAL
Intervention: AF ablation in patients with a history of decompensated TIC who maintained sinus rhythm or had paroxysmal AF (group 1)
Number of subjects: 674
Study 24762049 — intervention group
Group type: EXPERIMENTAL
Intervention: AF ablation in patients with a history of decompensated TIC who had persistent or longstanding persistent AF (group 2)
Number of subjects: 674
Study 24762049 — intervention group
Group type: EXPERIMENTAL
Intervention: AF ablation in patients without TIC who had paroxysmal AF (group 3)
Number of subjects: 674
Study 24762049 — intervention group
Group type: EXPERIMENTAL
Intervention: AF ablation in patients without TIC who had persistent or longstanding persistent AF (group 4)
Number of subjects: 674
Study 24762049 — intervention group
Group type: COMPARATOR
Intervention: Heart rate control during AF without sinus conversion
Number of subjects: 674
Study 23263427 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse formulated from ethanol extract of Terminalia chebula
Number of subjects: 60
Study 20975266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous CD34+ stem cells
Number of subjects: 112
Study 20975266 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary saline injections (placebo control)
Number of subjects: 112
Study 18476420 — intervention group
Group type: EXPERIMENTAL
Intervention: Gengxueting (GXT) one capsule every day for 90 consecutive days before surgical operation
Number of subjects: 64
Study 18476420 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 64
Study 16247305 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted fluoroscopic ORIF technique
Number of subjects: 30
Study 16247305 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopic-assisted ORIF technique
Number of subjects: 30
Study 12401046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral force applied from the canine region at a 30 degrees angle to the occlusal plane
Number of subjects: 20
Study 12401046 — intervention group
Group type: COMPARATOR
Intervention: Extraoral force applied 20 mm above the maxillary occlusal plane
Number of subjects: 20
Study 10024334 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 188
Study 10024334 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 188
Study 7580006 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonal‐F (225 IU/day, SC)
Number of subjects: 20
Study 7580006 — intervention group
Group type: COMPARATOR
Intervention: Metrodin (225 IU/day, IM)
Number of subjects: 20
Study 2311334 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nicotine patch
Number of subjects: 0
Study 6778345 — intervention group
Group type: EXPERIMENTAL
Intervention: PCP-8 (octavalent vaccine) administered at 25 micrograms of each serotype at 3-6 months and again at 18-24 months.
Number of subjects: 71
Study 6778345 — intervention group
Group type: EXPERIMENTAL
Intervention: PCP-7 or PCP-8 administered to 44 infants followed for two years.
Number of subjects: 71
Study 6778345 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (control group).
Number of subjects: 71
Study 6778345 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural infection or immunization.
Number of subjects: 71
Study 6778345 — intervention group
Group type: EXPERIMENTAL
Intervention: PCP immunization.
Number of subjects: 71
Study 31431077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional, automated text messages prior to the procedure
Number of subjects: 71
Study 31431077 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study 28348190 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing Intervention Package (SIP) delivered pre-treatment
Number of subjects: 0
Study 28348190 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (control group)
Number of subjects: 0
Study 26471791 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face, group-based intervention (six, theory-based two-hour sessions delivered over 8 weeks targeting healthy eating and physical activity)
Number of subjects: 174
Study 26471791 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 174
Study 26471791 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face, group-based intervention
Number of subjects: 174
Study 23421568 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 15
Study 23421568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 20626736 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular saline flushes of ECC
Number of subjects: 10
Study 20626736 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 10
Study 20626736 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69 ST membrane after ECC priming
Number of subjects: 10
Study 19806814 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of aprotinin (500,000 KIU, 50 mL)
Number of subjects: 128
Study 19806814 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (50 mL)
Number of subjects: 128
Study 17052775 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 2.5 mg/day (group A)
Number of subjects: 137
Study 17052775 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with folic acid, group B)
Number of subjects: 137
Study 17052775 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 2.5 mg/day (group A) in patients with MTHFR 677TT mutation
Number of subjects: 137
Study 15030340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexarotene gel monotherapy
Number of subjects: 55
Study 11601949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for dementia, details on dosage and duration not available
Number of subjects: 0
Study 11601949 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of medications and health conditions, details not available
Number of subjects: 0
Study 11601949 — intervention group
Group type: EXPERIMENTAL
Intervention: Early identification strategies, details not available
Number of subjects: 0
Study 9484373 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (400 mg)
Number of subjects: 55
Study 9484373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 8045623 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming drugs
Number of subjects: 200
Study 8045623 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapies
Number of subjects: 200
Study 2839729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control (tc) with normal mean HbA1 levels < 8.6% (n = 50)
Number of subjects: 83
Study 2839729 — intervention group
Group type: COMPARATOR
Intervention: Poor control (pc) with abnormal mean HbA1 levels ≥ 8.6% (n = 33)
Number of subjects: 83
Study 2839729 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-controlled patients with initially abnormal peripheral nerve tests
Number of subjects: 83
Study 2839729 — intervention group
Group type: COMPARATOR
Intervention: Well-controlled patients with normal nerve tests at baseline
Number of subjects: 83
Study 31564582 — intervention group
Group type: EXPERIMENTAL
Intervention: BASIL model in JUVENTAS cohort
Number of subjects: 0
Study 31564582 — intervention group
Group type: EXPERIMENTAL
Intervention: PREVENT III model in JUVENTAS cohort
Number of subjects: 0
Study 31564582 — intervention group
Group type: EXPERIMENTAL
Intervention: BASIL model in JUVENTAS population
Number of subjects: 0
Study 31564582 — intervention group
Group type: EXPERIMENTAL
Intervention: FINNVASC model in PADI population
Number of subjects: 0
Study 31564582 — intervention group
Group type: EXPERIMENTAL
Intervention: All models in each population
Number of subjects: 0
Study 30096354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous ranibizumab (0.5 mg)
Number of subjects: 305
Study 28314813 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (atDCS)
Number of subjects: 48
Study 28314813 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (stDCS)
Number of subjects: 48
Study 25991654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 1582
Study 25991654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 1582
Study 25991654 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 1582
Study 25991654 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 1582
Study 25991654 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1582
Study 25991654 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 1582
Study 25991654 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 1582
Study 23072926 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral unsaturated fat load test (OFLT)
Number of subjects: 32
Study 23072926 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 32
Study 21501131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Number of subjects: 42
Study 21501131 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation
Number of subjects: 42
Study 19435154 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor coordination training for 20 minutes daily over 3 weeks
Number of subjects: 53
Study 19435154 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor coordination training for children with balance problems
Number of subjects: 53
Study 19435154 — intervention group
Group type: COMPARATOR
Intervention: Control group (received training after posttest)
Number of subjects: 53
Study 16938683 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management group intervention based on the Self-Management of Well-being (SMW) theory
Number of subjects: 100
Study 16938683 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 15511345 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning catheter tip in central area of the endometrial cavity (relative position analysis)
Number of subjects: 400
Study 15511345 — intervention group
Group type: COMPARATOR
Intervention: Positioning catheter tip in absolute positions (absolute position analysis)
Number of subjects: 400
Study 11477728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1 mg
Number of subjects: 9
Study 11477728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9554816 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day for >1 year)
Number of subjects: 24
Study 9554816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7810179 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 51
Study 7810179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal diet
Number of subjects: 51
Study 7810179 — intervention group
Group type: COMPARATOR
Intervention: Control group (without zinc supplementation)
Number of subjects: 51
Study 7810179 — intervention group
Group type: COMPARATOR
Intervention: Control group (without cereal diet)
Number of subjects: 51
Study 3122335 — intervention group
Group type: COMPARATOR
Intervention: Standard amino acid solutions
Number of subjects: 0
Study 3122335 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA enriched solutions
Number of subjects: 0
Study 29294910 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling behavior by a romantic partner
Number of subjects: 0
Study 29294910 — intervention group
Group type: EXPERIMENTAL
Intervention: Feelings of passionate love
Number of subjects: 0
Study 29294910 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline reports of at least one form of ARA
Number of subjects: 0
Study 29294910 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (female respondents)
Number of subjects: 0
Study 30316341 — intervention group
Group type: EXPERIMENTAL
Intervention: Living kidney related donations (LKRD)
Number of subjects: 2683
Study 27152523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (4x/week for 4 weeks)
Number of subjects: 57
Study 27152523 — intervention group
Group type: COMPARATOR
Intervention: No activity (control group)
Number of subjects: 57
Study 26435241 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Border®
Number of subjects: 111
Study 26435241 — intervention group
Group type: COMPARATOR
Intervention: Zetuvit® with Cosmopor E®
Number of subjects: 111
Study 26435241 — intervention group
Group type: COMPARATOR
Intervention: Zetuvit® with Opsite Post‐Op Visible®
Number of subjects: 111